中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2012年
6期
763-766
,共4页
万能斌%张理%左朝晖%何潇%林劲冠%潘曙光%尹彬%罗威%朱海珍%欧阳永忠
萬能斌%張理%左朝暉%何瀟%林勁冠%潘曙光%尹彬%囉威%硃海珍%歐暘永忠
만능빈%장리%좌조휘%하소%림경관%반서광%윤빈%라위%주해진%구양영충
胃肿瘤/外科学/药物疗法%抗肿瘤联合化疗方案/治疗应用%高温,诱发%注射,腹腔内%氟尿嘧啶/投药和剂量
胃腫瘤/外科學/藥物療法%抗腫瘤聯閤化療方案/治療應用%高溫,誘髮%註射,腹腔內%氟尿嘧啶/投藥和劑量
위종류/외과학/약물요법%항종류연합화료방안/치료응용%고온,유발%주사,복강내%불뇨밀정/투약화제량
Stomach neoplasms/surgery/drug therapy%Antineoplastic combined chemotherapy protocols/therapeutic use%Hyperthermia,induced%Injections,intraperitoneal%Fluorouracil/administration & dosage
目的 探讨进展期胃癌根治术中腹腔内温热化疗联合缓释氟尿嘧啶植入的临床安全性.方法 回顾性分析本院2002年9月至2011年9月收治的280例进展期胃癌的临床资料,按治疗方法分三组研究.对三组并发症、死亡率和累积生存率进行比较.结果 三组并发症比较差异无统计学意义(P＞0.05),腹腔内温热化疗联合缓释氟脲嘧啶植入组术后5年复发率(16.18％)低于腹腔内温热化疗组(37.61％)和单纯手术组(41.28％),差异均有统计学意义(P＜0.05).腹腔内温热化疗联合缓释氟尿嘧啶植入组1,3和5年累积生存率分别为85.51％ 、61.28％和53.67％,腹腔内温热化疗组1,3和5年累积生存率分别为84.11％、39.98％和28.12％,单纯手术组1,3和5年累积生存率分别为81.28％、29.88％和25.21％.三组1年累积生存率比较差异无统计学意义(P＞0.05),而腹腔内化疗联合缓释氟尿嘧啶植入组3和5年累积生存率显著高于腹腔内温热化疗组和单纯手术组(P＜0.05).结论 进展期胃癌根治术中腹腔内温热化疗联合缓释氟尿嘧啶植入的临床治疗是一种简单、安全和有效的综合治疗方法,具有杀灭腹腔游离的癌细胞,可降低术后的复发率和提高生存率.
目的 探討進展期胃癌根治術中腹腔內溫熱化療聯閤緩釋氟尿嘧啶植入的臨床安全性.方法 迴顧性分析本院2002年9月至2011年9月收治的280例進展期胃癌的臨床資料,按治療方法分三組研究.對三組併髮癥、死亡率和纍積生存率進行比較.結果 三組併髮癥比較差異無統計學意義(P＞0.05),腹腔內溫熱化療聯閤緩釋氟脲嘧啶植入組術後5年複髮率(16.18％)低于腹腔內溫熱化療組(37.61％)和單純手術組(41.28％),差異均有統計學意義(P＜0.05).腹腔內溫熱化療聯閤緩釋氟尿嘧啶植入組1,3和5年纍積生存率分彆為85.51％ 、61.28％和53.67％,腹腔內溫熱化療組1,3和5年纍積生存率分彆為84.11％、39.98％和28.12％,單純手術組1,3和5年纍積生存率分彆為81.28％、29.88％和25.21％.三組1年纍積生存率比較差異無統計學意義(P＞0.05),而腹腔內化療聯閤緩釋氟尿嘧啶植入組3和5年纍積生存率顯著高于腹腔內溫熱化療組和單純手術組(P＜0.05).結論 進展期胃癌根治術中腹腔內溫熱化療聯閤緩釋氟尿嘧啶植入的臨床治療是一種簡單、安全和有效的綜閤治療方法,具有殺滅腹腔遊離的癌細胞,可降低術後的複髮率和提高生存率.
목적 탐토진전기위암근치술중복강내온열화료연합완석불뇨밀정식입적림상안전성.방법 회고성분석본원2002년9월지2011년9월수치적280례진전기위암적림상자료,안치료방법분삼조연구.대삼조병발증、사망솔화루적생존솔진행비교.결과 삼조병발증비교차이무통계학의의(P＞0.05),복강내온열화료연합완석불뇨밀정식입조술후5년복발솔(16.18％)저우복강내온열화료조(37.61％)화단순수술조(41.28％),차이균유통계학의의(P＜0.05).복강내온열화료연합완석불뇨밀정식입조1,3화5년루적생존솔분별위85.51％ 、61.28％화53.67％,복강내온열화료조1,3화5년루적생존솔분별위84.11％、39.98％화28.12％,단순수술조1,3화5년루적생존솔분별위81.28％、29.88％화25.21％.삼조1년루적생존솔비교차이무통계학의의(P＞0.05),이복강내화료연합완석불뇨밀정식입조3화5년루적생존솔현저고우복강내온열화료조화단순수술조(P＜0.05).결론 진전기위암근치술중복강내온열화료연합완석불뇨밀정식입적림상치료시일충간단、안전화유효적종합치료방법,구유살멸복강유리적암세포,가강저술후적복발솔화제고생존솔.
Objective To investigate clinical application of intraoperative intraperitoneal hyperthermic chemotherapy using sustained-release fluorouracil in radical gastrectomy for advanced gastric cancer.Methods The clinical data of 280 advanced gastric cancer patients admitted from September,2002 to September,2010 were analyzed retrospectively.They were divided into three groups randomly and followed up.The postoperative morbidity,the mortality and the overall survival rates were evaluated.Results There were no significant differences in these three groups with respect to postoperative morbidity ( P ＞ 0.05 ).The incidence of recurrence in intraperitoneal chemotherapy using sustained-release fluorouracil ( treatment group) was significantly lower than those of intraperitoneal chemotherapy and operative treatment( 16.18％,37.61％ and 41.28％,P ＜0.05).The 1,3- and 5-year overall survival rates of treatment group were 85.51％,61.28％ and 53.67％,respectively,and the 1-,3- and 5-year overall survival rates were 84.11％,39.98％ and 28.12％,and 81.28％,29.88％ and 25.21％ respectively in intrapeitoneal chemotherapy group and operative group.1-year overall survival rate had no significant differences among three groups with respect to ( P＞0.05).3-and 5-year overall survival rates in treatment group were higher signfficantly than those of intraperitoneal chemotherapy and operative treatment( P＜0.05).Conclusions Intraoperative intrapeitoneal hyperthermic chemotherapy using sustained-release fluorouracil is a kind of convenient,safe,and highly effective comprehensive treatment method,and it can kill isolated intraperitoneal cancer cells.It may reduce postoperative recurrence and improve survival rates.
